Literature DB >> 3296121

[Therapeutic effects of trazodone in the treatment of tremor. Multicentric double-blind study].

F Sanson, E Schergna, D Semenzato, C P Trevisan, M Bizzarini, F Violante, I Santagostino, C Ravenna, G Maccarone.   

Abstract

A 30 days therapeutical trial with trazodone has been performed in 47 patients suffering from different types of tremor. No significant improvement was detected in patients suffering from parkinsonian syndromes, multiple sclerosis, psycogenic tremor and hyperthyroidism. After the double-blind trial with trazodone, a significant improvement (p less than 0.025) was, instead, evident in 5 out of 6 patients with essential tremor, while the score did not change in the 3 patients with essential tremor who were treated with placebo.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3296121

Source DB:  PubMed          Journal:  Riv Neurol        ISSN: 0035-6344


  5 in total

Review 1.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

Review 2.  Linking Essential Tremor to the Cerebellum: Neurochemical Evidence.

Authors:  Juan Marin-Lahoz; Alexandre Gironell
Journal:  Cerebellum       Date:  2016-06       Impact factor: 3.847

3.  Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson's disease.

Authors:  Adjia Hamadjida; Stephen G Nuara; Jim C Gourdon; Philippe Huot
Journal:  J Neural Transm (Vienna)       Date:  2017-12-15       Impact factor: 3.575

4.  Essential tremor: treatment options.

Authors:  William G Ondo
Journal:  Curr Treat Options Neurol       Date:  2006-05       Impact factor: 3.972

Review 5.  Current and Future Neuropharmacological Options for the Treatment of Essential Tremor.

Authors:  Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez; Félix J Jiménez-Jiménez
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.